Prima BioMed

Immutep to be acquired by Prima BioMed

Friday, October 3, 2014

Immutep, an Orsay, France-based, late stage private biopharmaceutical company focused on immuno-oncology, has reached an agreement to be acquired by Prima BioMed, a Sydney, Australiabased developer of personalized immunocellular therapeutic products for cancer. Prima will pay up to approximately $28 million through a combination of cash, shares and warrants, subject to the achievement of certain performance milestones.

[Read More]